Direct NAD+ precursor. Restores cellular NAD+ pools that decline with age. Note: nucleotide, not a peptide.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Direct precursor to NAD+ via the salvage pathway. Sinclair lab and Imai lab work motivates the longevity claim. Human RCTs (e.g., Yoshino 2021, Yamaguchi 2024) show modest insulin-sensitivity and biomarker effects; lifespan extrapolation is speculative.
FDA's 2022 stance complicates legal supplement sale in the US. Bioavailability of oral NMN vs. its metabolite NR is debated. Quality of grey-market product varies.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Major proponent of NMN as NAD+ precursor for healthspan extension. Lab-published mouse data shows improved mitochondrial function and exercise capacity. Sinclair has been outspoken about personal use; controversial within the broader longevity research community.
Skeptical of oral NMN as the right NAD+ precursor — argues nicotinamide riboside (NR) and dietary niacin equivalents are better-evidenced and lower-cost. Has publicly criticized Sinclair's marketing of NMN-based products and the 'NAD+ supplement' category broadly.
Multiple short human trials (4-12 weeks) show modest blood-NAD+ elevation, walking-speed improvements, and aerobic-capacity changes. Long-term outcomes (cardiovascular, cancer-incidence, all-cause mortality) absent. Effect sizes smaller than supplement marketing suggests.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 500-1000 mg · daily, oral
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 500-1000 mg daily oral
NMN is regulatorily a supplement (not a peptide drug); sold by mainstream supplement companies. Wide quality range — third-party HPLC verification varies. FDA notice in 2022 attempted to challenge supplement classification; matter unresolved.
As of 2026-04FDA pulled supplement status 2022; available as research compound